Evidence map›Paper›PMID 38739047›Full record

Trial reportInternational journal of radiation oncology, biology, physics2024

Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp Trial.

Elizabeth A Hahn, Stephanie L Pugh, Hien L Lu, Alyssa M Vela, Erin F Gillespie, Elizabeth M Nichols, Jean L Wright, Shannon M MacDonald, Oren Cahlon, Carole Baas and 15 more

Abstract readValidation StudyRandomized Controlled TrialPragmatic Clinical Trial
In one paragraph

Trial report in International journal of radiation oncology, biology, physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Measurement properties of the USER-Participation Restriction subscale and PROMISQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Elizabeth A HahnDepartment of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Stephanie L PughAmerican College of Radiology, Philadelphia, Pennsylvania.
Hien L LuDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: Hien.lu@pennmedicine.upenn.edu.
Alyssa M VelaDepartment of Cardiac Surgery, Northwestern Feinberg School of Medicine, Chicago, Illinois.
Erin F GillespieDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Elizabeth M NicholsDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
Jean L WrightDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Shannon M MacDonaldDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Oren CahlonDepartment of Radiation Oncology, NYU Grossman School of Medicine, New York, New York.
Carole BaasAlamo Breast Cancer Foundation, San Antonio, Texas.
Lior Z BraunsteinDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
L Christine FangDepartment of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington.
Gary M FreedmanDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Rachel B JimenezDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Christy M KessleringKess Rx, Elmhurst, Illinois.
Mark V MishraDepartment of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland.
Robert W MutterDepartment of Radiation Oncology and Pharmacology, Mayo Clinic Axis School of Medicine, Rochester, Minnesota.
Nisha OhriDepartment of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Lane R RosenDepartment of Radiation Oncology, Willis-Knighton Health System, Shreveport, Louisiana.
James J UrbanicDepartment of Radiation Oncology, UC San Diego School of Medicine, San Diego, California.
Reshma JagsiDepartment of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia.
Sandra A MitchellDivision of Cancer Control and Population Sciences, National Institutes of Health, Bethesda, Maryland.
Justin E BekelmanDepartment of Radiation Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
David CellaDepartment of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Study Group Investigators:

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Leveraging implementation science to accelerate adoption of shorter-course radiation for breast and prostate cancerK08CA252640 · NCI · UNIVERSITY OF WASHINGTON · PI GILLESPIE, ERIN FAYE · 2020 to 2025
$1.3M
Intramural NIH HHS Z99 CA999999NCI NIH HHS K08 CA252640NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeOur purpose was to evaluate the measurement properties of patient-reported outcome (PRO) measures used in the ongoing RadComp pragmatic randomized clinical trial (PRCT). METHODS AND MATERIALS: The deidentified and blinded data set included 774 English-speaking female participants who completed their 6-month posttreatment assessment. Eleven PRO measures were evaluated, including the Trial Outcome Index from the Functional Assessment of Cancer Therapy-Breast (FACT-B), Satisfaction with Breast Cosmetic Outcomes, the BREAST-Q, and selected Patient-Reported Outcomes Measurement Information System (PROMIS) measures. PROs were measured at 3 timepoints: baseline, completion of radiation therapy (RT), and 6 months post-RT. Ten variables were used as validity anchors. Pearson or Spearman correlations were calculated between PROs and convergent validity indicators. Mean PRO differences between clinically distinct categories were compared with analysis of variance methods (known-groups validity). PRO change scores were mapped to change in other variables (sensitivity to change).

resultsMost correlations between PROs and validity indicators were large (≥0.5). Mean score for Satisfaction with Breast Cosmetic Outcomes was higher (better) for those with a lumpectomy compared with those with a mastectomy (P < .001). Mean scores for the FACT-B Trial Outcome Index and for PROMIS Fatigue and Ability to Participate in Social Roles and Activities were better for those with good baseline performance status compared with those with poorer baseline performance status (P < .05). At completion of RT and post-RT, mean scores for Satisfaction with Breast Cosmetic Outcomes and BREAST-Q Radiation were significantly different (P < .001) across categories for all Functional Assessment of Chronic Illness Therapy -Treatment Satisfaction - General items. There were medium-sized correlations between change scores for FACT-B Trial Outcome Index, Fatigue, Anxiety, and Ability to Participate in Social Roles and change scores in the Visual Analog Scale.

conclusionsFor patients with nonmetastatic breast cancer receiving radiation in the RadComp PRCT, our findings demonstrate high reliability and validity for important PRO measures, supporting their psychometric strength and usefulness to reflect the effect of RT on health-related quality of life.

Indexed as

Breast NeoplasmsPatient Reported Outcome MeasuresQuality of LifeAdultAgedFatigueFemaleHumansLymphatic IrradiationMiddle AgedPatient SatisfactionReproducibility of Results

Identifiers

PMID38739047
PMCPMC11329347

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.